Payment overview · 2025
General Payments
$146.02
8 reported records · 6 companies
Healthcare provider profile · identity verified
Cory Lee Cummings, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TYLER, TX · NPI 1366821928
Verified facts
What the public records show
CMS Open Payments records show Cory Lee Cummings, M.D. received $146.02 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.08 | 39.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.05 | 19.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.06 | 13.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.45 | 9.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.35 | 9.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.03 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.02 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 77 |
| Lisinopril | Lisinopril | 300 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 72 |
| Metformin Hcl | Metformin Hcl | 238 | 59 |
| Gabapentin | Gabapentin | 214 | 50 |
| Losartan Potassium | Losartan Potassium | 213 | 61 |
| Omeprazole | Omeprazole | 207 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 42 |
| Chlorthalidone | Chlorthalidone | 173 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 50 |
| Trazodone Hcl | Trazodone Hcl | 130 | 38 |
| Eliquis | Apixaban | 121 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 30 |
| Furosemide | Furosemide | 115 | 39 |
| Prednisone | Prednisone | 111 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 28 |
| Sertraline Hcl | Sertraline Hcl | 107 | 26 |
| Simvastatin | Simvastatin | 100 | 28 |
| Allopurinol | Allopurinol | 92 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Warfarin Sodium | Warfarin Sodium | 89 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 27 |
| Carvedilol | Carvedilol | 75 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 20 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Glimepiride | Glimepiride | 72 | 18 |
| Alprazolam | Alprazolam | 70 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 57 |
| Montelukast Sodium | Montelukast Sodium | 69 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 14 |
| Promethazine Hcl | Promethazine Hcl | 65 | 13 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 17 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Meloxicam | Meloxicam | 55 | 15 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Famotidine | Famotidine | 52 | 18 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Valsartan | Valsartan | 50 | 13 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Ozempic | Semaglutide | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 19 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Finasteride | Finasteride | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Relistor | Methylnaltrexone Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.02 · 8 records | ABBVIE INC. | AIRSUPRA, CREON, GEMTESA, LINZESS, Ozempic, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error